Mexico vs Peru: Average cost of drugs for extensively drug-resistant tuberculosis
Mexico
3,500 constant 2022 US$
in 2024
Peru
3,884 constant 2022 US$
in 2024
Mexico rank
19th
Peru rank
18th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mexico
- Peru
How they compare
Peru currently reports 3,884 constant 2022 US$ against 3,500 constant 2022 US$ in Mexico, a difference of 384 constant 2022 US$.
That makes Peru's figure about 1.1 times Mexico's.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Peru ahead.
Mexico ranks 19th and Peru ranks 18th of 56 countries.
Peru has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mexico | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,870 constant 2022 US$ | 21,788 constant 2022 US$ | 15,918 constant 2022 US$ | Peru |
| 2020s | 4,063 constant 2022 US$ | 6,019 constant 2022 US$ | 1,956 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mexico or Peru?
- Peru, at 3,884 constant 2022 US$ against 3,500 constant 2022 US$ in Mexico as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mexico and Peru?
- 384 constant 2022 US$, with Peru ahead.
- How many years of comparable data are there for Mexico and Peru?
- 8 years are reported by both, from 2017 to 2024.
- How do Mexico and Peru rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mexico ranks 19th and Peru ranks 18th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.